Proteostasis Therapeutics Inc. (Nasdaq: PTI) reported positive results from three studies, PTI-428, PTI-801 and PTI-808 to treat cystic fibrosis. Shares of the biopharmaceutical more than doubled by leaping $3.79 to close at $6.14.